Overview

A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects With T2DM

Status:
Enrolling by invitation

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

This trial is conducted in China. The aim of the trial is to compare the efficacy and safety of GZR101 and insulin degludec/insulin aspart in insulin naïve or insulin treated subjects with type 2 diabetes.

Phase:

Phase 2

Details

Lead Sponsor:

Gan and Lee Pharmaceuticals, USA

Treatments:

Insulin
Insulin Aspart